Mazdutide
GLP-1/GCG · s.c. · Innovent (Lilly licence)
Summary
- Also known as
- IBI362
- Mechanism
- GLP-1/GCG
- Route
- s.c.
- Company
- Innovent (Lilly licence)
- Highest development stage
- approved
- Status (as of data cut)
- Approved in China: obesity (June 2025) and T2D (September 2025); 9 mg supplementary NDA accepted (Nov 2025); GLORY-2 published (JAMA 2026) verify
- Next milestone
- 9 mg approval; GLORY-3 vs semaglutide
Sources for the status
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 4 approved / in label | NMPA (China), June 2025 | GLORY-1; NMPA approval (Jun 2025) |
| T2D | 4 approved / in label | NMPA (China), September 2025 | NMPA approval (Sep 2025) |
| CV outcomes | 2 phase 3 ongoing | Phase 3 ongoing | |
| CKD | 2 phase 3 ongoing | Phase 3 ongoing | |
| HFpEF | 1 phase 2 / signal | Phase 2 only | |
| MASH | 2 phase 3 ongoing | Phase 3 ongoing | |
| Sleep apnoea | 2 phase 3 ongoing | Phase 3 ongoing | |
| Knee OA | 0 no data | ||
| Alzheimer's | 2 phase 3 ongoing | Phase 3 in T2D with early cognitive impairment ongoing | LIGHT-COG |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
US prescribing information: indications
Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US phase 2 (NCT06124807) | 3-6 mg (3 mg to week 32) | obesity | 32 | 179 | −7.3 % vs −0.9 % Δ −6.4 pp | — | — | — | — | — | — | — | — | press release |
| US phase 2 (NCT06124807) | 10 mg | obesity | 32 | 179 | −15.6 % vs −0.9 % Δ −14.7 pp | — | — | — | — | — | — | — | — | press release |
| US phase 2 (NCT06124807) | 16 mg | obesity | 32 | 179 | −18.1 % vs −0.9 % Δ −17.2 pp | — | — | 20.0 | — | — | — | — | — | press release |
| DREAMS-1 | 4 mg | t2d china | 24 | 320 | — | −5.5 % vs −1.1 % Δ −4.3 pp | −1.6 vs −0.2 | — | — | — | — | — | — | press release |
| DREAMS-1 | 6 mg | t2d china | 24 | 320 | — | −7.3 % vs −1.1 % Δ −6.2 pp | −2.0 vs −0.2 | — | — | — | — | — | — | press release |
| DREAMS-2 | mazdutide 4 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 % | t2d china | 28 | — | — | −6.5 % | −1.6 | 2.1 | 8.7 | 35.5 | 24.0 | 5.8 | — | verified |
| DREAMS-2 | mazdutide 6 mg vs dulaglutide 1.5 mg: −2.77 % (treatment-policy); HbA1c −1.36; AE discontinuation 1.6 %; nausea 17.1 %; vomiting 14.3 % | t2d china | 28 | — | — | −8.5 % | −1.7 | 3.7 | 13.1 | 34.4 | 29.1 | 4.9 | — | verified |
| DREAMS-3 | 6 mg vs semaglutide 1 mg: weight -6.0 %, HbA1c -1.84 | t2d china | 32 | 349 | — | —−10.3 % estimand not specified | −2.0 | — | — | — | — | — | — | press release |
| GLORY-1 | mazdutide 4 mg | obesity china | 48 | — | — | −11.0 % vs +0.3 % Δ −11.3 pp | — | 1.5 vs 1.0 | 11.3 vs 5.4 | 32.5 vs 5.9 | 26.1 vs 2.9 | 5.9 vs 6.3 | — | verified |
| GLORY-1 | mazdutide 6 mg | obesity china | 48 | — | — | −14.0 % vs +0.3 % Δ −14.3 pp | — | 0.5 vs 1.0 | 10.9 vs 5.4 | 50.5 vs 5.9 | 43.1 vs 2.9 | 4.0 vs 6.3 | — | verified |
| GLORY-2 | mazdutide 9 mg | obesity china | 60 | — | −18.6 % vs −3.0 % Δ −15.5 pp | −16.6 % vs −1.5 % Δ −15.1 pp | — | 2.9 vs 0.0 | 13.0 vs 5.2 | 46.9 vs 3.2 | 53.1 vs 1.3 | 7.2 vs 5.2 | −9.8 vs −0.2 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- mazdutide 4 mg: Shown at week 48, the end of randomised placebo-controlled treatment, so that weight and safety cover the same period (atlas rule, see Method). Primary end point at week 32 (treatment-policy): −10.09 % vs +0.45 % with placebo. Efficacy-estimand values and HbA1c are in the supplement only.
- mazdutide 6 mg: Shown at week 48, the end of randomised placebo-controlled treatment, so that weight and safety cover the same period (atlas rule, see Method). Primary end point at week 32 (treatment-policy): −12.55 % vs +0.45 % with placebo. Efficacy-estimand values and HbA1c are in the supplement only.
- mazdutide 9 mg: Primary end point at week 60. Any-reason discontinuation computed from the completed-treatment counts (denominator 307 treated). HbA1c in the supplement only.
- mazdutide 4 mg: Active-controlled vs dulaglutide 1.5 mg; primary end point HbA1c at week 28. Any-reason discontinuation computed from the trial profile (Fig. 1). Efficacy-estimand weight in a figure only.
- mazdutide 6 mg: Active-controlled vs dulaglutide 1.5 mg; primary end point HbA1c at week 28. Any-reason discontinuation computed from the trial profile (Fig. 1). Efficacy-estimand weight in a figure only.
Verbatim quotes from the source (44)
- 3-6 mg (3 mg to week 32) · weight_eff · publication
At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
- 10 mg · weight_eff · publication
At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
- 16 mg · weight_eff · publication
At 32 weeks, the least-squares mean percentage change from baseline in bodyweight was -7·3% (SE 0·9) with mazdutide 3-6 mg, -15·6% (0·7) with 10 mg, and -18·1% (1·0) with 16 mg, versus -0·9% (0·8) with placebo.
- 16 mg · ae_dc · publication
discontinuation of study treatment due to adverse events occurred most frequently with 16 mg (20%)
- 4 mg · hba1c · press release
the adjusted least-squares (LS) mean changes in HbA1c from baseline at Week 24 were -1.58% for mazdutide 4 mg, -2.02% for mazdutide 6 mg, and -0.25% for placebo, respectively
- 4 mg · weight_tp · press release
the adjusted LS mean percentage weight changes from baseline at Week 24 were -5.50% for mazdutide 4 mg, -7.34% for mazdutide 6 mg, and -1.15% for placebo, respectively
- 6 mg · hba1c · press release
the adjusted least-squares (LS) mean changes in HbA1c from baseline at Week 24 were -1.58% for mazdutide 4 mg, -2.02% for mazdutide 6 mg, and -0.25% for placebo, respectively
- 6 mg · weight_tp · press release
the adjusted LS mean percentage weight changes from baseline at Week 24 were -5.50% for mazdutide 4 mg, -7.34% for mazdutide 6 mg, and -1.15% for placebo, respectively
- 6 mg · hba1c · press release
the mean change in HbA1c from baseline was −2.03% in the mazdutide group and −1.84% in semaglutide group
- 6 mg · weight_unsp · press release
the mean percentage weight reduction from baseline was 10.29% in the mazdutide group and 6.00% in the semaglutide group
- mazdutide 4 mg · weight_tp · Table 2 (week 48, key secondary end point)
| Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
- mazdutide 4 mg · ae_dc · Table 4
| Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5)
- mazdutide 4 mg · disc_any · Results, Participants, paragraph 1
trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
- mazdutide 4 mg · nausea · Table 4
| Nausea | 66 (32.5)
- mazdutide 4 mg · vomiting · Table 4
| Vomiting | 53 (26.1)
- mazdutide 4 mg · sae · Table 4
| Serious adverse event | 12 (5.9)
- mazdutide 6 mg · weight_tp · Table 2 (week 48, key secondary end point)
| Percentage change in body weight from baseline to wk 48 (95% CI) — % | -11.00 (-12.27 to -9.73) | -14.01 (-15.36 to -12.66) | 0.30 (-0.98 to 1.58) |
- mazdutide 6 mg · ae_dc · Table 4
| Adverse event leading to discontinuation of mazdutide or placebo | 3 (1.5) | 1 (0.5)
- mazdutide 6 mg · disc_any · Results, Participants, paragraph 1
trial regimen prematurely (23 participants [11.3%] in the 4-mg mazdutide group, 22 [10.9%] in the 6-mg mazdutide group, and 11 [5.4%] in the placebo group)
- mazdutide 6 mg · nausea · Table 4
| Nausea | 66 (32.5) | 102 (50.5)
- mazdutide 6 mg · vomiting · Table 4
| Vomiting | 53 (26.1) | 87 (43.1)
- mazdutide 6 mg · sae · Table 4
| Serious adverse event | 12 (5.9) | 8 (4.0)
- mazdutide 9 mg · weight_eff · Results, Coprimary Outcomes, paragraph 1 (eTable 1 in Supple
the mean percentage change in body weight from baseline to week 60 was -18.55% (95% CI, -19.78% to -17.31%) in the mazdutide group vs -3.02% (95% CI, -4.72% to -1.31%) in the placebo group
- mazdutide 9 mg · weight_tp · Table 2; Results, Coprimary Outcomes, paragraph 1
mean percentage change in body weight from baseline to week 60 was -16.65% (95% CI, -18.19% to -15.12%) in the mazdutide group vs -1.50% (95% CI, -3.43% to 0.43%) in the placebo group
- mazdutide 9 mg · ae_dc · Table 3
| Any that led to treatment discontinuation | 9 (2.9) | 0 | 2.9 (0.5 to 5.5) |
- mazdutide 9 mg · disc_any · Results, Participants; Figure 1
89.6% of participants (267 [87.0%] in the mazdutide group vs 146 [94.8%] in the placebo group) completed the treatment
- mazdutide 9 mg · nausea · Table 3
| Nausea | 144 (46.9) | 5 (3.2) | 43.7 (37.1 to 49.7) |
- mazdutide 9 mg · vomiting · Table 3
| Vomiting | 163 (53.1) | 2 (1.3) | 51.8 (45.7 to 57.5) |
- mazdutide 9 mg · sae · Table 3
| Serious adverse eventsa | 22 (7.2) | 8 (5.2) | 2.0 (-3.3 to 6.3) |
- mazdutide 9 mg · sbp · Results, Key Secondary Outcomes, paragraph 2; Table 2 (garbl
systolic blood pressure was -9.80 mm Hg (95% CI, -11.37 to -8.23 mm Hg) in the mazdutide group vs -0.23 mm Hg (95% CI, -2.13 to 1.67 mm Hg) in the placebo group
- mazdutide 4 mg · weight_tp · Results, Body weight paragraph 1; Table 2
with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
- mazdutide 4 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
TEAEs that led to study treatment discontinuation occurred in five (2.1%) participants who received 4 mg mazdutide
- mazdutide 4 mg · disc_any · Fig. 1 (trial profile)
N6[242 received at least one dose] --> N9[21 discontinued study treatment: Adverse event: 5 br Withdrawal by participant: 16]
- mazdutide 4 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
nausea (35.5%, 34.4% and 17.1%)
- mazdutide 4 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
vomiting (24.0%, 29.1% and 14.3%)
- mazdutide 4 mg · sae · Results, Safety paragraph 1; Table 3
adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
- mazdutide 4 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)
- mazdutide 6 mg · weight_tp · Results, Body weight paragraph 1; Table 2
with LS means of -6.55% (s.e. 0.332) with 4 mg mazdutide, -8.53% (0.346) with 6 mg mazdutide and -2.77% (0.329) with 1.5 mg dulaglutide reported under the treatment-policy estimand
- mazdutide 6 mg · ae_dc · Results, Safety paragraph 2; Table 3; Extended Data Table 2
nine (3.7%) who received 6 mg mazdutide and four (1.6%) who received 1.5 mg dulaglutide (Table 3 and Extended Data Table 2)
- mazdutide 6 mg · disc_any · Fig. 1 (trial profile)
N7[244 received at least one dose] --> N12[32 discontinued study treatment: Adverse event: 9 br Withdrawal by participant: 22 br Physician decision: 1]
- mazdutide 6 mg · nausea · Results, Safety paragraph 3; Table 3; Extended Data Table 3
nausea (35.5%, 34.4% and 17.1%)
- mazdutide 6 mg · vomiting · Results, Safety paragraph 3; Table 3; Extended Data Table 3
vomiting (24.0%, 29.1% and 14.3%)
- mazdutide 6 mg · sae · Results, Safety paragraph 1; Table 3
adverse events were reported in 14 participants (5.8%) who were treated with 4 mg mazdutide, 12 (4.9%) who were treated with 6 mg mazdutide and 19 (7.8%) who were treated with 1.5 mg dulaglutide
- mazdutide 6 mg · hba1c · Results, Glycaemic outcomes paragraph 1; Table 2
mean changes of -1.61% (standard error (s.e.) 0.061) with 4 mg mazdutide, -1.66% (0.062) with 6 mg mazdutide and -1.36% (0.060) with 1.5 mg dulaglutide (Table 2, and Fig. 2a)
Registered trials (14)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Hypertension | Phase 3 | recruiting | 2026-04 → 2026-08 | 336 | recruiting | NCT07469800 |
| NCT07255209 · China A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | Obesity | Phase 3 | recruiting | 2025-12 → 2027-10 | 180 | recruiting | NCT07255209 |
| LIGHT-COG Study Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study) | Alzheimer's | Phase 3 | recruiting | 2025-09 → 2029-08 | 420 | recruiting | NCT07083154 |
| GLORY-OSA A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | Sleep apnoea | Phase 3 | recruiting | 2025-06 → 2027-05 | 260 | recruiting | NCT06931028 |
| NCT06937749 A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | MASH | Phase 2 | active not recruiting | 2025-06 → 2026-09 | 181 | active not recruiting | NCT06937749 |
| GLORY-3 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | MASH | Phase 3 | active not recruiting | 2025-05 → 2026-12 | 479 | active not recruiting | NCT06884293 |
| NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | HFpEF | Phase 2 | active not recruiting | 2025-03 → 2026-09 | 141 | active not recruiting | NCT06862908 |
| NCT06817356 A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Addiction | Phase 2 | completed | 2025-02 → 2026-03 | 308 | Completed; results not in the atlas yet | NCT06817356 |
| NCT06519656 Efficacy of Mazdutide for Treating PCOS | Other | Phase 2 | completed | 2024-10 → 2026-09 | 43 | Completed; results not in the atlas yet | NCT06519656 |
| DREAMS-3 A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Obesity | Phase 3 | completed | 2024-02 → 2025-09 | 349 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT06184568 |
| GLORY-2 A Study of IBI362 9 mg in Chinese Adults With Obesity | Obesity | Phase 3 | unknown | 2023-12 → 2025-06 | 462 | unknown | NCT06164873 |
| DREAMS-2 A Study of IBI362 in Participants With Type 2 Diabetes | T2D | Phase 3 | completed | 2023-01 → 2024-01 | 731 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05606913 |
| NCT05628311 · China A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | T2D | Phase 3 | completed | 2023-01 → 2023-10 | 319 | Completed; results not in the atlas yet | NCT05628311 |
| GLORY-1 A Study of IBI362 in Participants With Obesity or Overweight | Obesity | Phase 3 | completed | 2022-11 → 2023-08 | 610 | Completed; arm-level results are in the atlas maps (Effect vs cost, Arms) | NCT05607680 |
Primary sources
- Hsia SH, Bays HE, Billings LK, Weideman AMK, Mather KJ, Coskun T, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026;14(11):879-893. PMID: 42628555.
- Innovent. Nature: Two Phase 3 Clinical Results of Mazdutide in Chinese Adults with Type 2 Diabetes Published Back-to-back (DREAMS-1, DREAMS-2) [press release]. 2025-12-17. Available from: https://www.prnewswire.com/news-releases/nature--two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature-302644606.html
- Innovent. Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3 [press release]. 2025-10-26. Available from: https://www.prnewswire.com/news-releases/innovents-mazdutide-shows-superiority-in-glycemic-control-with-weight-loss-over-semaglutide-in-a-head-to-head-phase-3-clinical-trial-dreams-3-302594633.html
- Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736.
- Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336(5):377-388. PMID: 42251595.
- Guo L, Zhang B, Xue X, Zhang X, Cai H, Jiang H, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652(8108):181-188. PMID: 41407860.
How to cite this page
Cite the primary publication for any single result; every value above links to it.